Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor

Article Abstract:

Research presented concerns the impact of catecholamine neurotransmitter dopamine on angiogenesis, focusing on the anti-tumor effect of dopamine. Findings suggest that dopamine works with D(sub)2 dopamine receptors, inducing vascular endothelial growth factor receptor 2 endocytosis, which is key to promoting angiogenesis, while also preventing the binding of vascular permeability factor/vascular endothelial growth factor, receptor phoshorylation, and the following signaling effects.

Author: Basu, Sujit, Nagy, Janice A., Pal, Soumitro, Eckelhoefer, Isabelle A., Bliss, V. Susan, Manseau, Eleanor J., Dasgupta, Partha S., Dvorak, Harold F., Mukhopadhyay, Debabrata, Vasile, ELiza
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2001
Research

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


The neurotransmitter dopamine inhibits angiogenesis induced by vasuclar permeability factor/vascular endothelial growth factor

Article Abstract:

Research suggests that the administration of dopamine at non-toxic levels inhibits angiogenesis induced by the malignant tumor-related cytokine vascular permeability factor/vascular endothelial growth factor (VPF/VEGF). Topics include the effect of dopamine on the movement and proliferation of human umbilical vein endothelial cells and how dopamine reduces VEGF receptor 2 binding and phosphorylation.

Author: Basu, Sujit, Nagy, Janice A., Pal, Soumitro, Vasile, Eliza, Eckelhoefer, Isabelle A., Bliss, V. Susan, Manseau, Eleanor J., Dasgupta, Partha S., Dvorak, Harold F., Mukhopadhyay, Debabrata
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2001
Cytokines

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A novel function for tissue inhibitor of metalloproteinases-3 (TMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2

Article Abstract:

The mechanism of inhibition of the vascular endothelial factor mediated angiogenesis by the tissue inhibitor of metalloproteinases-3 occurs by the enzyme's blocking the binding of the growth factor to its receptor thereby arresting downstream signaling.

Author: Qi, Jian Hua, Ebrahem, Quteba, Moore, Nina, Murphy, Gillian, Claesson-Welsh, Lena, Bond, Mark, Baker, Andrew, Anand-Apte, Bela
Publisher: Nature America, Inc.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2003
United Kingdom, Sweden, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Enzyme Inhibitors, Protein binding

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Statistical Data Included, United States, Neovascularization, Vascular endothelial growth factor, Dopamine, Neurotransmitters, Physiological aspects
Similar abstracts:
  • Abstracts: The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of antiogenic growth factors
  • Abstracts: Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. Estrogens, progestins, selective estrogen receptor modulators, and the arterial tree
  • Abstracts: Cocaine-induced coronary-artery vasoconstriction. Immediate angioplasty for acute myocardial infarction. Cardiovascular complications of cocaine use
  • Abstracts: Stem cell losses and gains in the US. Prostate cancer prevention trial launched
  • Abstracts: Gene transfer into CD4(super.+) T lymphocytes: green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.